Stockscreener 앱 받기
0.7151
0.17%
-0.0012
시간 외 거래:
.72
0.0049
+0.69%
Unity Biotechnology Inc 주식(UBX)의 최신 뉴스
HC Wainwright Issues Optimistic Forecast for UBX Earnings - Defense World
Unity Biotechnology stock hits 52-week low at $0.66 - Investing.com
Unity Biotechnology stock hits 52-week low at $0.66 By Investing.com - Investing.com India
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
HC Wainwright & Co. Downgrades Unity Biotechnology (LSE:0YC0) - Nasdaq
Unity Biotechnology (NASDAQ:UBX) Receives Neutral Rating from HC Wainwright - Defense World
Unity Biotech stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Nigeria
This United States Steel Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Unity Biotechnology (UBX) Downgraded Amid Strategic Shifts | UBX Stock News - GuruFocus
HC Wainwright Downgrades Unity Biotechnology to Neutral From Buy, Adjusts Price Target to $2 From $4 - marketscreener.com
Unity Biotechnology (UBX) Downgrade: HC Wainwright & Co. Cuts Pr - GuruFocus
Unity Biotechnology (UBX) Downgrade: HC Wainwright & Co. Cuts Price Target | UBX Stock News - GuruFocus
Biotech company once valued at $700 million slashes entire workforce - MSN
Unity Biotechnology (NASDAQ:UBX) Rating Lowered to “Neutral” at Mizuho - Defense World
Mizuho cuts Unity Biotech stock rating, slashes price target to $1 - Investing.com Nigeria
Mizuho Downgrades Unity Biotechnology to Neutral From Outperform After Diabetic Edema Treatment Misses Primary Endpoint, Cuts Price Target to $1 From $6 - marketscreener.com
Unity Biotechnology (UBX) Downgraded Amid Trials and Strategic N - GuruFocus
Unity Biotechnology (UBX) to Release Earnings on Tuesday - Defense World
Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce - MSN
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Renaissance Technologies LLC Sells 16,759 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX) - Defense World
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Bay Area biotech company lays off every single worker, including CEO - SFGATE
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
UNITY Biotechnology (UBX) Reports Promising 36-Week Results from ASPIRE Trial | UBX Stock News - GuruFocus
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study - TipRanks
UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force - marketscreener.com
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates - The Manila Times
UNITY Biotechnology Announces Complete 36-Week Results from - GlobeNewswire
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of - Bluefield Daily Telegraph
UNITY's New DME Treatment Rivals Aflibercept in Phase 2b Trial, Company Explores Strategic Options - Stock Titan
UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting - Nasdaq
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting - The Manila Times
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
Chardan Capital Brokers Decrease Earnings Estimates for UBX - Defense World
Form 8-KCurrent report - ADVFN
HC Wainwright Issues Positive Outlook for UBX Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Chardan Capital Reaffirms “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Unity Biotechnology Reports Q1 2025 Financials and Study Updates - TipRanks
H.C. Wainwright maintains $4 target on Unity Biotech stock - Investing.com Australia
Unity Biotechnology (UBX) Reports $16.9M in Cash, Prepares for F - GuruFocus
H.C. Wainwright maintains $4 target on Unity Biotech stock By Investing.com - Investing.com Nigeria
UNITY Biotechnology (UBX) Shows Promise with Senolytic UBX1325 i - GuruFocus
UNITY Biotechnology Announces Publication in NEJM Evidence - GlobeNewswire
Revolutionary DME Drug Maintains Vision Improvement for 12 Months After Just One Dose, NEJM Study Shows - Stock Titan
0.87%
0.19%
자본화:
|
볼륨(24시간):